In short
Clinical trials investigating Heparin Calcium are studying treatment strategies for people with acute venous thromboembolism who are also taking antiplatelet medicines. These trials aim to compare safety and bleeding risk, especially when full-dose anticoagulant therapy is used alone or together with antiplatelet therapy. The main study shown here is in adults with acute VTE.
Key points
- Clinical trials investigating Heparin Calcium are focused on treatment strategies for people with acute venous thromboembolism who are already taking antiplatelet medicine. The main trial listed is a Phase 3 study with 1,400 planned participants. It compares full-dose anticoagulant therapy alone with full-dose anticoagulant therapy plus antiplatelet treatment. The main endpoint is clinically relevant bleeding, including major bleeding and clinically relevant non-major bleeding. The study follows patients through the full-dose treatment period, up to 12 months.
Trial overview
The main clinical trial listed for Heparin Calcium is NCT05627375, also called BAT-VTE, which studies the best antithrombotic treatment in patients with acute venous thromboembolism who are taking antiplatelet therapy.
This is an interventional study, which means researchers assign treatments and compare outcomes between groups.
Who is being studied
The trial targets people with an acute venous thromboembolism event, which means a new blood clot in a vein.
It focuses on patients who are also taking antiplatelet medicine for secondary arterial prevention at the time the venous clot is diagnosed.
Treatments being compared
The study compares full-dose anticoagulant therapy alone with a combination of antiplatelet therapy and full-dose anticoagulant therapy.
The trial lists several study medicines, including Heparin Calcium as part of the anticoagulant options used in the study setting.
Other listed medicines include apixaban, warfarin, fondaparinux, dalteparin, tinzaparin, enoxaparin, acenocoumarol, and rivaroxaban, showing that the study compares multiple treatment approaches used in practice.
Study phase and size
The trial is in Phase 3, which is a later stage of research that tests treatment strategies in a larger group of patients.
The planned enrollment is 1,400 participants.
Outcomes being measured
The main outcome is clinically relevant bleeding, which combines major bleeding and clinically relevant non-major bleeding using ISTH definitions.
This bleeding outcome is measured at the end of the full-dose treatment period, or for up to 12 months.
The brief study aim is to show whether full-dose anticoagulant therapy alone is better than combining anticoagulant and antiplatelet therapy for lowering bleeding risk in this patient group.
What this means for patients
For patients, this trial is mainly about finding the safest treatment plan after a new venous blood clot when antiplatelet medicine is already being used.
The study does not focus on symptom relief alone; it focuses on whether one treatment strategy causes less important bleeding than another.
Because the trial is in Phase 3 and includes a large number of participants, it is designed to give stronger evidence about which treatment approach may be safer in this situation.